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ABSTRACT
Objectives: To investigate the role of cytokeratin-19 fragment (CYFRA21-1) in cervical lesions screening in high-risk hu-
man papillomavirus (HR-HPV) infected women.
Material and methods: The study was a retrospective study. First, the results of CYFRA21-1, cytology (TCT), and HR-HPV 
examinations of 1039 outpatients from gynecology department in Tumor Hospital Affiliated to Xinjiang Medical University 
were collected. Then, the data was analyzed using a series of statistical methods. 
Results: There was a correlation between CYFRA21-1 levels and HPV-DNA load in HR-HPV infected women (rs = 0.711, 
p = 0.015). CYFRA21-1 levels and positive rate increased along with deepening of cervical cell lesions. In HR-HPV infected 
women, there was a statistically significant difference (t = 6.022, p < 0.001) in CYFRA21-1 levels between the group with 
cytological lesions (4.87 ± 1.58 ng/mL) and the group with normal cytology (2.52 ± 0.96 ng/mL). Positive rates of CY-
FRA21-1 in the two groups were 62.06% and 7.83%, respectively, and also exhibited statistically significant differences 
(χ2 = 74.624, p < 0.001). When diagnosing cytological lesions via CYFRA21-1 in HR-HPV infected women, sensitivity was 
62.07%, specificity was 92.17%, positive predictive value was 88.89%，negative predictive value was 70.67%. Compared 
to CYFRA21-1 negative women, cytological lesions were detected 19.273 times more often in CYFRA21-1 positive women. 
Conclusion: CYFRA21-1 could provide a reference idea for further diagnosis of women who are infected with HR-HPV but 
whose cytology is normal.
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INTRODUCTION
Human papillomavirus (HPV) is a type of virus which 
tends to parasitize epithelial cells. A HPV infection could 
lead to hyperplasia in a variety of squamous epithelial tis-
sues, such as cervical squamous epithelial cells, esophageal 
squamous cells and so on [1–3]. CYFRA21-1 widely exists in 
layered and squamous epithelial cells and, when a malignant 
hyperplasia occurs in squamous cells, the levels of serum 
CYFRA21-1 rise [4]. Cervical malignant lesions or cervical 
cancer are caused by a persistent infection with high-risk 
HPV (HR-HPV) which leads to immortalized hyperplasia of 
cervical epithelial cells [5]. HR-HPV includes hpv16, hpv18, 
hpv31, hpv33, hpv35, hpv45, hpv51, hpv52, hpv56, hpv58, 
hpv61 and so on. 90%~95% of cervical cancer is squamous 
cell carcinoma, so the goal is to research the relationship 
between the pathological changes in exfoliated cervical 
cells and CYFRA21-1 in HR-HPV infected women and thus 
to help to shunt screen HR-HPV infected women in the 
gynecology clinic.
MATERIAL AND METHODS
The source of the sample
The data was collected from outpatients who visited the 
gynecology clinic in Tumor Hospital Affiliated to Xinjiang 
Medical University between July 1st, 2011 and July 31st, 
2014. The results of their CYFRA21-1, HR-HPV-DNA and Thin-
prep Cytology Test (TCT, a liquid-based cytology method) 
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were obtained through the hospital laboratory information 
system. The data of those outpatients whose TCT result in-
dicated adenocarcinoma was excluded. Ultimately, data of 
1039 outpatients, aged between 18 years old and 71 years 
old, with a median age of 47 years old, was collected.
Detection methods
HR-HPV test used the Digene HPV Test kit (Digene Cor-
poration, USA) and related instruments (9700 GeneAmp 
PCR System etc.), and its principle was to generate results 
using the hybrid capture II method (HCII). The result of HCII 
was expressed via RLU value, the value of relative light 
units/cutoff value (threshold). RLU value represented the 
HR-HPV-DNA load in cervical epithelial cells. A RLU value 
greater than 1.0 was deemed to indicate positive HR-HPV 
infection. CYFRA21-1 was detected using Abbott i2000 au-
tomatic micro particle chemiluminescence analyzer and 
original kits. Reference interval for CYFRA21-1 levels was 
0~3.3 ng/mL; a value greater than 3.3 ng/mL was considered 
to be a positive result for CYFRA21-1. TCT results were ex-
pressed through terms used in cervical cytological diagnosis 
of TBS classification system, including Within Normal Limits 
(WNL), Atypical Squamous Cells (ASC), Low-grade Squa-
mous Intraepithelial Lesions (LSIL), High-grade Squamous 
Intraepithelial Lesion (HSIL) and Squamous Cell Carcinoma 
(SCC). Positive cytological diagnosis included any lesions 
classified as ASC or above.
Statistical methods
Statistical analyses were performed using the SPSS sta-
tistics software version 17.0. Data was presented as x  ± SD, 
median (M) and quarterback spacing (Q). Quantitative vari-
ables of two independent groups were compared using 
the parametric Student t-test. Spearman rank correlation 
analysis was used for assessing the correlation between the 
two indexes. Quantitative variables of many independent 
groups were compared using one-way analysis of variance 
(ANOVA) and if the difference in results was statistically sig-
nificant, then the Dunnett-T3 method was used to compare 
every pair of groups. Positive rates between different groups 
were compared using χ2 test. Significance level was α = 0.05, 
p < 0.05 indicated statistical significance.
RESULTS
General data statistics
Out of 1039 cases which formed the sample, there were 
231 cases of women testing positively for HR-HPV infection; 
the positive rate was 22.91%. In 87 cases CYFRA21-1 tests 
indicated positive results; the positive rate was 8.37%. In 
121 cases TCT results were positive; the positive rate was 
12.22%.
The correlation between HR-HPV-DNA load  
and CYFRA21-1
CYFRA21-1 levels (2.79 ± 0.82 ng/mL) in HR-HPV posi-
tive cases showed a statistically significant difference 
(t = 5.014, p < 0.001) compared to HR-HPV negative cases 
(1.36 ± 0.51 ng/mL). Due to the fact that HPV-DNA quantita-
tive variables showed skewness in distribution in HR-HPV 
infected cases, they are presented using the median (M) and 
quarterback spacing (Q), which are 5.78 and 42.37, respec-
tively. In Spearman rank correlation analysis, HPV-DNA load 
showed correlation with CYFRA21-1 (rs = 0.711, p = 0.015).
The difference in CYFRA21-1 levels  
and positive rates between different  
cervical cell lesions groups
Based on TCT results, 1039 cases which formed the sam-
ple were divided into four groups: negative group (912 cas-
es) including WNL women, Low lesion group (61 cases) 
including ASC and LSIL women, Moderate lesion group 
(40 cases) including HSIL women and Severe lesion group 
(26 cases) including SCC women. CYFRA21-1 test results 
for all four groups are shown in Table 1. ANOVA (F = 47.382, 
p < 0.001) showed statistically significant differences in CY-
FRA21-1 levels among the four groups; Dunnett-T3 method 
was subsequently employed and showed that statistical 
differences existed between any two groups (p < 0.001). 
CYFRA21-1 positive rates in the four groups also showed 
statistical significance (χ2 = 522.300, p < 0.001).
The correlation between cervical lesions  
and CYFRA21-1 in HR-HPV infected women
Of 231 patients with HR-HPV infection, 115 cases showed 
no cytological pathological changes. CYFRA21-1 was com-
pared between HR-HPV+TCT– cases and HR-HPV+TCT+ cas-
es. Comparative results are shown in Table 2.
CYFRA21-1 used to diagnose cervical cell lesions 
in HR-HPV infected cases
When diagnosing cervical cell lesions in HR-HPV in-
fected women as shown in Table 3, sensitivity was 62.07%, 
Table 1. The comparison of CYFRA21-1 levels and positive rates 
between different cervical lesion groups
Group N
CYFRA21-1
Levels 
[ng/mL]
Positive rate
(%)
Negative group 912 1.36 ± 0.54 1.64
Low lesion group 61 2.79 ± 0.79 37.71
Moderate lesion group 40 5.05 ± 1.38 60.00
Severe lesion group 26 9.86 ± 0.82 96.15
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specificity was 92.17%, positive predictive value was 
88.89%, negative predictive value was 70.67%. The odds 
ratio (OR) of diagnosing cervical cell lesions in positive CY-
FRA21-1 cases compared to negative CYFRA21-1 cases was 
19.273; 95% CI was 8.861–41.917. It means that cervical cell 
lesions are 19.273 times more likely to appear in positive 
CYFRA21-1 cases than in negative CYFRA21-1 cases.
DISCUSSION
Harald zur Hauser proved that HR-HPV infection is a high 
risk factor of squamous cell carcinomas in the 1970s [6]. Re-
cent studies have shown that persistent HR-HPV infections 
are closely related to malignant lesions of cervical epithelial 
cells. Therefore, HR-HPV test has been incorporated into the 
process of screening for cervical lesions in women. Currently, 
the most widely used clinical screening system for cervical 
lesions in women in the gynecology clinic is HPV testing in 
combination with TCT examination. CYFRA21-1 is a common 
serum tumor marker of squamous cell carcinoma which has 
a certain significance in auxiliary diagnosis of cervix lesions 
[7–10]. In this study, during the statistical analysis of gynecol-
ogy clinic outpatients, several observations were made. First, 
it was found that CYFRA21-1 levels exhibit obvious differ-
ences between HR-HPV positive and HR-HPV negative popu-
lations. Next, it was discovered that a clear positive correlation 
(rs = 0.711) exists between HR-HPV-DNA and CYFRA21-1 in 
HR-HPV infected population. It means that HR-HPV infection 
could affect CYFRA21-1 levels; therefore, CYFRA21-1 could 
help in shunt screening for cervical malignant lesions in 
HR-HPV infected patients in the gynecology clinic.
In 127 cases of TCT positive patients, the study found 
that the levels and positive rates of CYFRA21-1 have been 
increasing following deepening of cervical lesions, which is 
consistent with previous reports [11]. Because CYFRA21-1 as 
a serum tumor marker is not as closely related to cervical le-
sions as HR-HPV-DNA, in the low-grade and moderate lesion 
groups there were some negative CYFRA21-1 cases. To sum 
up, in HR-HPV infected women, CYFRA21-1 and HR-HPV virus 
load had good correlation, and the serum concentration 
of CYFRA21-1 increased along with deepening of cervical 
lesions. It could therefore be used in auxiliary diagnosis of 
cervical lesion index for suspicious cervical lesions; positive 
CYFRA21-1 could also prompt further diagnosis of cervical 
lesions.
Due to the fact that HR-HPV testing combined with TCT 
is the most commonly used screening method [12–16], 
the question of how to further shunt screening is a com-
mon problem in case of HR-HPV positive but TCT nega-
tive patients. Clinicians usually consider HR-HPV positive 
patients to have suspected cervical lesions, so the differ-
ence in expression of CYFRA21-1 between HPV+TCT+ and 
HPV+TCT– groups is very significative. This study found that 
the levels and positive rates of CYFRA21-1 show significant 
differences between HPV+TCT+ and HPV +TCT– patients.
For further study, diagnosing cervical lesions using CY-
FRA21-1 in HR-HPV infected women had good specificity, 
equal to 92.17%. Previous reports suggest that CYFRA21-1 as 
a tumor marker has high sensitivity and low specificity in 
diagnosis of HPV infected cervical cancer [17], which does 
not match the results of this study. This inconsistency may be 
the result of different research objects: the object of previous 
reports was HPV infected cervical cancer, but the object of 
this study were HR-HPV infected cervical lesions in patients.
This study also found that appearance of cervical lesions 
in positive CYFRA21-1 cases was 19.273 times more likely 
compared to negative CYFRA21-1 cases in all HR-HPV infected 
women. Results of further CYFRA21-1 tests for HR-HPV infect-
ed patients indicating positive CYFRA21-1 denote two pos-
sibilities: first, TCT may have a false negative cytology, which 
prompts the doctor to reexamine TCT or perform further cy-
tology checks; second, positive CYFRA21-1 means that occur-
rence of cervical cell lesions in the future is much more likely, 
which requires patients to shorten the interval between fol-
low-up cytological examinations in order to quickly discover 
any future cervical cell lesions. Conversely, if CYFRA21-1 is in 
the normal range or at a very low level, the interval between 
follow-up examinations could be appropriately relaxed in the 
future, reducing economic burden for the patients.
CONCLUSIONS
There was certain clinical significance of CYFRA21-1 for 
shunting to screen cervical lesions in HR-HPV infected wo- 
men. However, the study only encompassed 238 cases of 
HR-HPV infected patients; the sample number was small. 
Also, the positive cutoff value of CYFRA21-1 in the study was 
taken from the testing laboratory reference range; a more 
Table 2. The expression of CYFRA21-1 in different HR-HPV infected 
cases
N
CYFRA21-1
Levels
[ng/mL]*
Positive rate
(%)**
HR-HPV+TCT– 115 2.52 ± 0.96 7.83
HR-HPV+TCT+ 116 4.87 ± 1.58 62.06
*t = 6.022, p < 0.001;**χ2 = 74.624, p < 0.001; both showed statistically 
significant differences
Table 3. The values of CYFRA21-1 used to diagnose cervical cell 
lesions in HR-HPV infected cases
TCT+ TCT-
HR-HPV+CYFRA21-1+ 72 9
HR-HPV+CYFRA21-1– 44 106
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detailed study should be performed to obtain a more sig-
nificant cutoff value of CYFRA21-1 for shunt screening the 
HR-HPV infected population.
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